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MAJOR CHANGES IN LEVELS OF REGULATORY CYTOKINES AND FUNCTIONAL ANTIBOD-
IES CONTRIBUTE TO SEVERE IMMUNODEFICIENCY OF MYELOMA PATIENTS AND PER-
SIST AT ONE YEAR POST DIAGNOSIS 
Chicca I.J., Heaney J.L.J., Iqbal G., Bowcock S., Planche T., Wood J.,
Raynes K., Hawkey P., Pratt G., Yong K., Dunn J.A., Drayson M.T.
Clinical Immunology Service University of Birmingham, Warwick Clinical
Trial Unit University of Warwick, King’s College Hospital NHS Trust, De-
partment of Medical Microbiology St George’s University of London, Depart-
ment of Medical Microbiology, West Midlands Public Health Laboratory
Heart of England NHS Trust, University Hospital Birmingham NHS Trust,
Department of Haematology UCL Cancer Institute, UK
Introduction. Multiple myeloma is associated with severe immunodefi-
ciency and increased susceptibility to infections. Bacterial infections are re-
current and a major cause of morbidity in myeloma patients. Cytokines
interleukin-10 (IL-10) and -13 (IL-13) are regarded as anti-inflammatory
which down regulate innate immune functions against infections. Interleu-
kin-7 (IL-7) has been shown to promote myeloma growth through the inhi-
bition of osteoblast differentiation. Acting together immunoparesis (a
reduction in normal polyclonal immunoglobulin levels below the lower limit
of normal) and the dysregulation of cytokine network may contribute to in-
creased susceptibility to bacterial infections, perpetuation of inflammation
and disease development. This study investigated functional antibodies levels
and IL-7, IL-10 and IL-13 at disease presentation, in response to induction
treatment and in remission in the UK Tackling Early Morbidity and Mortality
in Myeloma trial (TEAMM). Method Serum samples at disease presentation,
after 12 weeks of therapy and after 1 year were collected from 890 multiple
myeloma patients (aged 35–90 years old) enrolled in TEAMM. Multiplex
Luminex assay was used for the analysis of IgG antibody levels against 19
bacterial antigens (12 pneumococcal (Pn), 4 meningococcal (Men), haemo-
philus influenza b (HiB) polysaccharide, and diphtheria and tetanus toxoids)
and of serum cytokines IL-7, IL-10 and IL-13. Anti-bacterial antibodies and
cytokines levels from patients with myeloma were compared to healthy blood
donors. Results A significantly lower proportion of myeloma patients de-
monstrated protective levels against all bacterial antigens compared to the
healthy donors (p<0.05) (see Table attached). At disease presentation, less
than 6% of multiple myeloma patients had serum IgG antibodies above the
WHO 0.35 µg/mL protective threshold for at least 8 of the 12 investigated
Pn serotypes. A higher proportion of patients aged < 65 years old were pro-
tected against Men serotypes, HiB and tetanus while more patients in the ≥
65 age group were protected against Pn serotypes which may result from UK
vaccination of 65 year olds with pneumovax. Following induction therapy,
serum IgGs levels against all investigated bacteria were significantly lower
than presentation levels (p<0.01). Regulatory cytokines IL-7, IL-10 and IL-
13 were significantly higher in TEAMM patients compared to healthy vo-
lunteer (p<0.05) at disease presentation, after induction therapy and during
remission. Patients who had suffered episodes of infection during TEAMM
trial presented higher concentrations of IL-7 compared to patients without
infection episodes (p<0.05). Discussion This study shows anti-bacterial im-
munological responses are severely compromised in a large population of
multiple myeloma patients. The overwhelming majority of patients failed to
meet protective levels of functional antibodies and after treatment these levels
are significantly reduced even further. Regulatory cytokines were elevated
in myeloma patients compared to healthy controls suggesting their involve-
ment in the down-regulation of immune responses to bacterial infection and
in multiple myeloma disease progression. This project is funded by the Effi-
cacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR
partnership. The views expressed in this publication are those of the author(s)
and not necessarily those of the MRC, NHS, NIHR or the Department of He-
alth. 
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